Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles.
Adult
Biomarkers
/ blood
Blood Glucose
/ drug effects
Case-Control Studies
Cross-Sectional Studies
Diabetes Mellitus, Type 1
/ blood
Dyslipidemias
/ blood
Female
Glycemic Control
Humans
Hypoglycemic Agents
/ therapeutic use
Lipoproteins, LDL
/ blood
Magnetic Resonance Spectroscopy
Male
Middle Aged
Spain
/ epidemiology
Advanced lipoprotein profile
LDL-particles
Lipoproteins
Nuclear magnetic resonance spectroscopy
Type 1 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
09 08 2020
09 08 2020
Historique:
received:
10
05
2020
accepted:
25
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
18
5
2021
Statut:
epublish
Résumé
Lipoprotein disturbances have been associated with increased cardiovascular disease (CVD) risk in type 1 diabetes mellitus (T1DM). We assessed the advanced lipoprotein profile in T1DM individuals, and analysed differences with non-diabetic counterparts. This cross-sectional study involved 508 adults with T1DM and 347 controls, recruited from institutions in a Mediterranean region of Spain. Conventional and advanced (assessed by nuclear magnetic resonance [NMR] spectroscopy) lipoprotein profiles were analysed. Crude and adjusted (by age, sex, statin use, body mass index and leukocyte count) comparisons were performed. The median (interquartile range) age of the study participants was 45 (38-53) years, 48.2% were men. In the T1DM group, the median diabetes duration was 23 (16-31) years, and 8.1% and 40.2% of individuals had nephropathy and retinopathy, respectively. The proportion of participants with hypertension (29.5 vs. 9.2%), and statin use (45.7% vs. 8.1%) was higher in the T1DM vs. controls (p < 0.001). The T1DM group had a better conventional (all parameters, p < 0.001) and NMR-lipid profile than the control group. Thus, T1DM individuals showed lower concentrations of atherogenic lipoproteins (VLDL-particles and LDL-particles) and higher concentrations of anti-atherogenic lipoproteins (HDL-particles) vs. controls, even after adjusting for several confounders (p < 0.001 for all). While non-diabetic women had a more favourable lipid profile than non-diabetic men, women with T1DM had a similar concentration of LDL-particles compared to men with T1DM (1231 [1125-1383] vs. 1257 [1128-1383] nmol/L, p = 0.849), and a similar concentration of small-LDL-particles to non-diabetic women (672.8 [614.2-733.9] vs. 671.2 [593.5-761.4] nmol/L, respectively; p = 0.790). Finally, T1DM individuals showed higher discrepancies between NMR-LDL-particles and conventional LDL-cholesterol than non-diabetic subjects (prevalence of LDL-cholesterol < 100 mg/dL & LDL-particles > 1000 nmol/L: 38 vs. 21.2%; p < 0.001). All these differences were largely unchanged in participants without lipid-lowering drugs (T1DM, n = 275; controls, n = 317). Overall, T1DM participants showed a more favourable conventional and NMR-lipid profile than controls. However, the NMR-assessment identified several lipoprotein derangements in LDL-particles among the T1DM population (higher discrepancies in NMR-LDL-particles vs. conventional LDL-cholesterol; a worse profile in T1DM women) that were overlooked in the conventional analysis. Further studies are needed to elucidate their role in the development of CVD in this population.
Sections du résumé
BACKGROUND
Lipoprotein disturbances have been associated with increased cardiovascular disease (CVD) risk in type 1 diabetes mellitus (T1DM). We assessed the advanced lipoprotein profile in T1DM individuals, and analysed differences with non-diabetic counterparts.
METHODS
This cross-sectional study involved 508 adults with T1DM and 347 controls, recruited from institutions in a Mediterranean region of Spain. Conventional and advanced (assessed by nuclear magnetic resonance [NMR] spectroscopy) lipoprotein profiles were analysed. Crude and adjusted (by age, sex, statin use, body mass index and leukocyte count) comparisons were performed.
RESULTS
The median (interquartile range) age of the study participants was 45 (38-53) years, 48.2% were men. In the T1DM group, the median diabetes duration was 23 (16-31) years, and 8.1% and 40.2% of individuals had nephropathy and retinopathy, respectively. The proportion of participants with hypertension (29.5 vs. 9.2%), and statin use (45.7% vs. 8.1%) was higher in the T1DM vs. controls (p < 0.001). The T1DM group had a better conventional (all parameters, p < 0.001) and NMR-lipid profile than the control group. Thus, T1DM individuals showed lower concentrations of atherogenic lipoproteins (VLDL-particles and LDL-particles) and higher concentrations of anti-atherogenic lipoproteins (HDL-particles) vs. controls, even after adjusting for several confounders (p < 0.001 for all). While non-diabetic women had a more favourable lipid profile than non-diabetic men, women with T1DM had a similar concentration of LDL-particles compared to men with T1DM (1231 [1125-1383] vs. 1257 [1128-1383] nmol/L, p = 0.849), and a similar concentration of small-LDL-particles to non-diabetic women (672.8 [614.2-733.9] vs. 671.2 [593.5-761.4] nmol/L, respectively; p = 0.790). Finally, T1DM individuals showed higher discrepancies between NMR-LDL-particles and conventional LDL-cholesterol than non-diabetic subjects (prevalence of LDL-cholesterol < 100 mg/dL & LDL-particles > 1000 nmol/L: 38 vs. 21.2%; p < 0.001). All these differences were largely unchanged in participants without lipid-lowering drugs (T1DM, n = 275; controls, n = 317).
CONCLUSIONS
Overall, T1DM participants showed a more favourable conventional and NMR-lipid profile than controls. However, the NMR-assessment identified several lipoprotein derangements in LDL-particles among the T1DM population (higher discrepancies in NMR-LDL-particles vs. conventional LDL-cholesterol; a worse profile in T1DM women) that were overlooked in the conventional analysis. Further studies are needed to elucidate their role in the development of CVD in this population.
Identifiants
pubmed: 32772924
doi: 10.1186/s12933-020-01099-0
pii: 10.1186/s12933-020-01099-0
pmc: PMC7416413
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Hypoglycemic Agents
0
Lipoproteins, LDL
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Références
Diabetes Care. 2020 Jan;43(1):178-186
pubmed: 31597668
Diabetes Metab Res Rev. 2020 Apr 2;:e3320
pubmed: 32239693
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Atherosclerosis. 2017 Aug;263:7-14
pubmed: 28550710
J Clin Med. 2019 Nov 05;8(11):
pubmed: 31694246
Diabetes Care. 2019 Jul;42(7):1284-1289
pubmed: 30894365
Cardiovasc Diabetol. 2018 May 4;17(1):66
pubmed: 29728117
Trends Endocrinol Metab. 2020 Jun;31(6):422-434
pubmed: 32217073
J Pediatr Endocrinol Metab. 2019 Apr 24;32(4):327-334
pubmed: 30860978
Ther Adv Endocrinol Metab. 2017 Nov;8(11):149-157
pubmed: 29114384
Atherosclerosis. 2016 Apr;247:161-9
pubmed: 26921744
BMJ Open. 2017 Jun 11;7(6):e015158
pubmed: 28606902
J Lipid Res. 2015 Mar;56(3):737-46
pubmed: 25568061
PLoS One. 2015 Aug 28;10(8):e0136348
pubmed: 26317989
Prog Nucl Magn Reson Spectrosc. 2013 Apr;70:1-24
pubmed: 23540574
Circulation. 2014 Feb 4;129(5):553-61
pubmed: 24345402
Int J Cardiol. 2018 Aug 1;264:172-178
pubmed: 29628276
J Diabetes Complications. 2016 May-Jun;30(4):657-68
pubmed: 26997169
Diabetes Metab Res Rev. 2020 Apr 7;:e3323
pubmed: 32266782
Cardiovasc Diabetol. 2018 Dec 19;17(1):158
pubmed: 30567548
Diabetes. 2002 Jun;51(6):1949-56
pubmed: 12031985
J Clin Lipidol. 2017 Mar - Apr;11(2):551-561.e7
pubmed: 28502513
Diabet Med. 2001 Oct;18(10):786-96
pubmed: 11678968
Diabetes Ther. 2020 Jan;11(1):161-174
pubmed: 31792784
Cardiovasc Diabetol. 2019 Mar 28;18(1):43
pubmed: 30922315
Diabetes. 2010 Jul;59(7):1771-9
pubmed: 20393149
Atherosclerosis. 2019 Jan;280:14-20
pubmed: 30453116
J Intern Med. 2013 Apr;273(4):383-95
pubmed: 23279644
Eur J Nutr. 2019 Sep;58(6):2271-2279
pubmed: 30019088
J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350
pubmed: 30423393
Diabetes Care. 2003 Mar;26(3):810-8
pubmed: 12610042
Atherosclerosis. 2020 Feb;294:46-61
pubmed: 31928713
Diabetes Obes Metab. 2018 Mar;20(3):556-563
pubmed: 28884949
Circulation. 2017 Apr 18;135(16):1522-1531
pubmed: 28416524
Diabetologia. 2017 Oct;60(10):2084-2091
pubmed: 28711972
Diabetes Care. 2014 Oct;37(10):2843-63
pubmed: 25114297
Lancet. 2018 Aug 11;392(10146):477-486
pubmed: 30129464
Diabetes Care. 1992 Jul;15(7):886-94
pubmed: 1516509
N Engl J Med. 2014 Nov 20;371(21):1972-82
pubmed: 25409370
Lancet Diabetes Endocrinol. 2015 Mar;3(3):198-206
pubmed: 25660575
Atherosclerosis. 2016 Jan;244:93-100
pubmed: 26600440
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetologia. 2011 Jan;54(1):78-86
pubmed: 20886205
Cardiovasc Diabetol. 2012 Dec 27;11:156
pubmed: 23270560
J Clin Lipidol. 2011 Mar-Apr;5(2):105-13
pubmed: 21392724
Circulation. 2019 Apr 16;139(16):1900-1912
pubmed: 30798638
Cardiovasc Diabetol. 2019 May 4;18(1):58
pubmed: 31054573
Atherosclerosis. 2013 Oct;230(2):347-53
pubmed: 24075767
Curr Diab Rep. 2018 Oct 17;18(12):127
pubmed: 30328521
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Diabetol Metab Syndr. 2017 Jun 26;9:48
pubmed: 28674557
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Clin Endocrinol Metab. 2020 Jan 1;105(1):
pubmed: 31529047